TESARO, Inc. (NASDAQ:TSRO) was upgraded by equities researchers at Leerink Swann from a “market perform” rating to an “outperform” rating in a research note issued to investors on Wednesday. Leerink Swann also issued estimates for TESARO’s Q4 2017 earnings at ($2.79) EPS, FY2017 earnings at ($8.61) EPS, FY2018 earnings at ($7.75) EPS, FY2019 earnings at ($5.22) EPS, FY2020 earnings at ($2.11) EPS and FY2021 earnings at $0.49 EPS.

Several other brokerages also recently weighed in on TSRO. Citigroup Inc. reaffirmed a “buy” rating and set a $216.00 price target on shares of TESARO in a report on Monday, September 11th. Robert W. Baird reaffirmed a “neutral” rating and set a $140.00 price target (down previously from $155.00) on shares of TESARO in a report on Thursday, August 10th. Jefferies Group LLC reaffirmed a “hold” rating and set a $124.00 price target on shares of TESARO in a report on Friday, November 3rd. Credit Suisse Group set a $190.00 price target on shares of TESARO and gave the company a “buy” rating in a report on Friday, August 18th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of TESARO in a report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $161.72.

TESARO (NASDAQ:TSRO) traded down $2.10 on Wednesday, hitting $85.90. 449,793 shares of the company were exchanged, compared to its average volume of 1,031,102. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34. TESARO has a one year low of $84.42 and a one year high of $192.94.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. During the same quarter last year, the firm posted ($1.72) earnings per share. The firm’s revenue was up 740.3% compared to the same quarter last year. equities research analysts predict that TESARO will post -8.18 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/17/tesaro-inc-tsro-rating-increased-to-outperform-at-leerink-swann.html.

In other TESARO news, Director James O. Armitage sold 10,000 shares of the business’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $1,171,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the transaction, the vice president now owns 6,258 shares in the company, valued at approximately $844,329.36. The disclosure for this sale can be found here. Insiders sold 35,692 shares of company stock worth $4,628,976 in the last 90 days. 40.50% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its position in TESARO by 5.7% during the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after acquiring an additional 195,590 shares during the last quarter. Vanguard Group Inc. increased its position in TESARO by 2.1% during the second quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after acquiring an additional 62,104 shares during the last quarter. State Street Corp increased its position in TESARO by 17.9% during the second quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock valued at $163,496,000 after acquiring an additional 177,057 shares during the last quarter. Janus Henderson Group PLC increased its position in TESARO by 24.9% during the third quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock valued at $115,616,000 after acquiring an additional 178,406 shares during the last quarter. Finally, BB Biotech AG increased its position in TESARO by 6.5% during the second quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock valued at $122,796,000 after acquiring an additional 53,408 shares during the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.